查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916222

前列腺特異性膜抗原抑制劑市場按分子類型、癌症分期、治療線、給藥途徑、患者年齡層、應用和最終用戶分類－2026-2032年全球預測

Prostate-Specific Membrane Antigen Inhibitor Market by Molecule Type, Cancer Stage, Treatment Line, Administration Route, Patient Age Group, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年前列腺特異性膜抗原抑制劑市值為 6.8732 億美元，預計到 2026 年將成長至 7.0467 億美元，預計到 2032 年將達到 8.7632 億美元，複合年成長率為 3.53%。

關鍵市場統計數據
基準年 2025 6.8732億美元
預計年份：2026年 7.0467億美元
預測年份 2032 8.7632億美元
複合年成長率 (%) 3.53%

對現代PSMA抑制劑的研發和應用所涉及的科學原理、臨床需求和操作複雜性進行嚴謹的概述

前列腺特異性膜抗原 (PSMA) 抑制劑已成為前列腺癌診斷影像和標靶治療交叉領域的關鍵藥物。這些藥物利用前列腺癌細胞中 PSMA 的過度表現，實現精準的腫瘤可視化和細胞毒性藥物的選擇性遞送，從而構建了一個整合診斷和治療目的的統一診療一體化框架。 PSMA治療診斷學的臨床應用涵蓋了從早期檢測到晚期疾病管理的各個階段，並且該技術對各種成像平台和放射性配體偶聯物的適應性，重新激發了臨床醫生、監管機構和投資者的濃厚興趣。

放射化學、治療診斷學、監管清晰度和供應鏈模式等領域的創新融合如何重塑PSMA抑制劑的競爭地位

近年來，科學創新、監管路徑和商業性預期方面的變革性轉變共同重塑了PSMA抑制劑的格局。放射化學和偶聯技術的進步，使治療手段從單株抗體擴展到結構緊密的小分子，從而實現了更快的腫瘤滲透和更多樣化的給藥途徑。同時，治療診斷學模式的成熟，使得診斷影像檢查不再是下游步驟，而是病患選擇、治療反應評估和適應性治療計畫不可或缺的一部分，進而影響臨床結果和醫保報銷。

評估貿易政策和關稅制度的變化將如何影響放射性藥物的採購經濟性、供應鏈韌性和區域製造策略。

調整關稅和貿易壁壘的政策決定將對放射性藥物的研發、生產和分銷的經濟效益產生重大影響。對臨床同位素、特殊前驅物或放射性藥物生產所需設備徵收或提高稅收，會增加製造商和合約服務提供者的投入成本。這些額外成本會波及整個採購管道，促使企業重新評估籌資策略、將生產集中到低成本地區以及採取同位素供應對沖策略。因此，贊助公司可能會加快對當地放射化學基礎設施的投資，或尋求供應協議以實現生產內部化，從而降低跨國關稅風險。

全面的細分分析揭示了應用類型、分子類別、疾病階段、治療線、護理環境、給藥途徑和年齡層如何影響產品策略。

細緻的細分框架揭示了臨床、商業性和營運方面的優先事項在不同應用、分子類別、疾病狀態、治療方案、最終用戶、給藥途徑和患者群體中的異同之處。從應用角度來看，診斷影像和治療途徑需要不同的能力。診斷影像強調高解析度PET和SPECT的兼容性以及與診斷檢查室和影像中心的流程整合，而治療則需要放射性配體或小分子藥物方面的專業知識，以及放射性鹵化物和放射性金屬偶聯能力和治療後安全性監測。就分子類型而言，單株抗體（包括嵌合體和人源化抗體）具有成熟的蛋白質工程和監管先例，而磷醯胺類和脲類藥物等小分子藥物則具有生產製程簡化和藥物動力學特性良好的優勢，支持更廣泛的給藥策略。

區域臨床和商業性趨勢正在推動PSMA診斷和治療在美洲、歐洲、中東和非洲以及亞太地區的應用路徑各不相同。

區域趨勢造就了不同的臨床、監管和商業性環境，進而影響PSMA抑制劑計畫的開發和部署。在美洲，先進的影像基礎設施、許多地區已建立的新型診斷報銷機制以及集中的臨床卓越中心，使得臨床試驗的快速招募和治療性診斷方法的早期應用成為可能。然而，公立和私立醫療系統之間支付方的差異，使得制定客製化的定價和證據產生策略成為必要。在歐洲、中東和非洲地區，監管的多樣性以及區域間在獲取專業放射性藥物生產能力​​方面的差異，往往導致集中式生產模式與新興的本地化生產模式並存。相關人員必須仔細考慮影響計畫實施時間表的各種報銷政策和轉診途徑。

競爭與合作並存的產業趨勢強調配體創新、放射化學規模化生產以及策略聯盟，以實現臨床優勢和供應鏈安全。

在競爭激烈的市場環境中，企業組織策略凸顯了對整合能力的重視，這些能力涵蓋藥物發現、放射化學放大生產、臨床檢驗和商業物流等各個環節。創新生物技術公司致力於最佳化配體設計、提高親和性，並開發能夠同時實現影像和治療結合的小分子結構。傳統製藥公司則利用其監管方面的專業知識、生產規模和與支付方的良好關係，加速後期研發進程，並與醫療系統和集團採購組織（GPO）協商供應協議。同時，專業的放射性藥物生產商和合約研發生產機構（CDMO）正在拓展其同位素處理、自動化合成以及無菌填充包裝能力，以滿足放射性配體療法的獨特需求。

為經營團隊將科學創新、供應鏈韌性、監管合作和以支付方為中心的證據產生整合到PSMA專案中的實用建議

產業領導者必須採取積極主動的策略，將科學發展與供應鏈韌性、監管互動以及以支付方為中心的證據產生結合。首先，應優先考慮平台柔軟性，並投資於適用於成像和治療的配體化學和偶聯技術。平台的多功能性能夠加快新適應症的上市速度，並實現臨床試驗資源的有效利用。其次，為降低供應側風險，應透過同位素來源多元化和建立區域性生產夥伴關係關係，減少對單一地區的依賴。近岸外包和合作生產協議能夠確保即使在貿易環境動盪的情況下，也能保障臨床供應。

我們採用可重複且透明的調查方法，結合專家訪談、技術文獻綜述和交叉檢驗的情境分析，為策略決策提供支援。

本分析整合了結構化的一手和二手研究證據，並進行了嚴格的交叉檢驗，以確保結論的可靠性和有效性。一手研究包括對臨床研究人員、放射性藥物部門負責人、法規事務負責人和商業決策者的訪談，以收集有關試驗設計、生產限制和支付方談判的真實世界見解。二手研究納入了同行評審的臨床研究、監管指導文件、臨床試驗註冊資訊以及放射化學和偶聯方法的技術文獻，以成熟的科學依據支持我們的發現。我們使用一個可複製的框架對這些資料來源進行三角驗證，該框架整合了臨床證據、操作可行性和商業性影響。

整合策略要務：臨床創新、營運規劃和相關人員協作如何整合，以推進PSMA標靶治療的交付

PSMA抑制劑領域已發展成為一個複雜的生態系統，科學創新、生產能力、監管合規和支付方期望相互交織，共同決定臨床影響和商業性成功。診斷影像和治療方法的相互依存日益加深，為整合產品策略創造了機遇，從而實現精準的患者選擇和標靶治療。同時，同位素採購、放射性藥物分發能力和區域醫療保健系統結構等運作現實因素，對新型治療方法如何以及何時惠及患者有顯著影響。對於渴望在該領域佔據領先地位的機構而言，基於嚴謹證據生成、供應鏈多元化和早期相關人員參與的清晰策略至關重要。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 前列腺特異性膜抗原抑制劑市場（依分子類型分類）

  • 單株抗體
    • 嵌合體體
    • 人性化
  • 低分子化合物
    • 磷醯胺
    • 基於尿素

9. 前列腺特異性膜抗原抑制劑市場依癌症分期分類

  • 晚期
  • 在地化
  • 轉移性

10. 前列腺特異性膜抗原抑制劑市場依治療線分類

  • 主要治療
  • 二級治療
  • 三級治療

11. 前列腺特異性膜抗原抑制劑市場依給藥途徑分類

  • 靜脈注射
  • 口服

12. 依患者年齡層別分類的前列腺特異性膜抗原抑制劑市場

  • 65至74歲
  • 75歲或以上
  • 65歲以下

13. 前列腺特異性膜抗原抑制劑市場（依應用分類）

  • 診斷影像檢查
    • PET影像
    • SPECT影像
  • 治療
    • 放射性配體療法
      • 放射性鹵化物絡合物
      • 放射性金屬共軛物
    • 小分子療法

14. 前列腺特異性膜抗原抑制劑市場（依最終用戶分類）

  • 癌症治療中心
    • 私人的
    • 公共機構
  • 診斷檢查室
  • 醫院藥房
  • 研究所

15. 前列腺特異性膜抗原抑制劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 前列腺特異性膜抗原抑制劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 各國前列腺特異性膜抗原抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章美國前列腺特異性膜抗原抑制劑市場

19. 中國前列腺特異性膜抗原抑制劑市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Blue Earth Diagnostics Ltd
  • Cardinal Health, Inc.
  • Curium US LLC
  • Eckert & Ziegler AG
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Pfizer Inc.
  • RayzeBio, Inc.
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited
Product Code: MRR-AE420CB15314

The Prostate-Specific Membrane Antigen Inhibitor Market was valued at USD 687.32 million in 2025 and is projected to grow to USD 704.67 million in 2026, with a CAGR of 3.53%, reaching USD 876.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 687.32 million
Estimated Year [2026] USD 704.67 million
Forecast Year [2032] USD 876.32 million
CAGR (%) 3.53%

A rigorous overview of the scientific rationale, clinical imperatives, and operational complexities defining contemporary PSMA inhibitor development and deployment

Prostate-specific membrane antigen (PSMA) inhibitors have emerged as pivotal agents at the intersection of diagnostic imaging and targeted therapy for prostate malignancies. These agents exploit the overexpression of PSMA on prostate cancer cells to enable precise tumor visualization and to deliver cytotoxic payloads selectively, thereby creating a unified theranostic framework that aligns diagnostics with therapeutic intent. The clinical trajectory of PSMA inhibitors spans early detection through advanced disease management, and the modality's adaptability across imaging platforms and radioligand conjugates has catalyzed renewed interest among clinicians, regulators, and investors.

Against this backdrop, stakeholders face complex trade-offs involving clinical efficacy, manufacturing complexity, regulatory rigor, and payer acceptance. Diagnostic applications require high specificity and reproducibility across PET and SPECT imaging protocols, while therapeutic applications demand scalable radiochemistry, cold-chain logistics, and robust safety monitoring. The development lifecycle for PSMA-targeted agents also intersects with evolving standards for companion diagnostics and biomarker-driven trial designs, which in turn shape clinical adoption. As a result, strategic decisions made today about modality selection, manufacturing partnerships, and clinical positioning will determine the competitive landscape for years to come. This report synthesizes the scientific advances and commercial realities that inform those decisions, offering a rigorous synthesis of the technical, clinical, and operational dimensions that define the PSMA inhibitor domain.

How converging innovations in radiochemistry, theranostics, regulatory clarity, and supply chain models are reshaping competitive positioning for PSMA inhibitors

Recent years have seen transformative shifts across scientific innovation, regulatory pathways, and commercial expectations that together are redefining the PSMA inhibitor landscape. Advances in radiochemistry and conjugation approaches have expanded the therapeutic armamentarium from monoclonal antibody constructs to compact small molecules that enable faster tumor penetration and diversified administration routes. Concurrently, the maturation of theranostic paradigms means that diagnostic imaging is no longer a downstream activity but an integral component of patient selection, response assessment, and adaptive treatment planning, which has both clinical and reimbursement implications.

Regulatory frameworks have adapted to accommodate these hybrid products, emphasizing evidence generation for safety and efficacy while expecting manufacturers to demonstrate consistent production quality for radioligands and conjugates. Payer communities are increasingly focused on value-based outcomes, driving trials toward clinically meaningful endpoints beyond surrogate imaging metrics. In parallel, supply chain and manufacturing models have evolved: decentralized radiopharmacy networks and contract radiopharmaceutical manufacturers are scaling processes to meet localized demand while sponsors invest in scalable radiochemistry to mitigate isotope scarcity. These shifts interact dynamically; scientific advances enable new clinical uses, regulatory clarity promotes strategic investment, and commercial realities shape how therapies are priced and delivered at scale.

Assessing how changes in trade policy and tariff regimes can alter procurement economics, supply chain resilience, and regional manufacturing strategies for radiopharmaceuticals

Policy decisions that adjust tariffs and trade barriers can materially influence the economics of radiopharmaceutical development, manufacturing, and distribution. New or increased tariffs on clinical-grade isotopes, specialized precursors, or the equipment required for radiopharmaceutical production can raise input costs for manufacturers and contract service providers. These added costs reverberate through procurement channels, prompting re-evaluation of sourcing strategies, concentration of manufacturing in lower-cost jurisdictions, and hedging strategies for isotope supply. In turn, sponsors may accelerate investments in local radiochemistry infrastructure or pursue supply agreements that internalize production to reduce exposure to cross-border tariff risk.

Moreover, tariff-driven cost increases can slow the adoption curve in cost-sensitive care settings, particularly where reimbursement models remain constrained. Health systems and diagnostic laboratories may defer capital investments in cyclotrons, automated synthesis modules, or new imaging suites if operating margins are compressed. Conversely, the policy environment can incentivize nearshoring and strategic partnerships, which over time strengthen regional manufacturing ecosystems and create more resilient cold-chain logistics. Finally, tariffs influence collaboration patterns: multinational collaborations may be structured to minimize tariff liabilities, for example by transferring non-tariffable know-how or by localizing certain manufacturing steps. In sum, tariff changes act as a catalytic variable that shapes cost structures, supply chain architecture, and long-term industrial strategy for radiopharmaceutical stakeholders.

Comprehensive segmentation analysis revealing how application types, molecule classes, disease stage, treatment lines, care settings, routes, and age cohorts shape product strategies

A nuanced segmentation framework reveals where clinical, commercial, and operational priorities converge and diverge across applications, molecule classes, disease states, treatment lines, end users, administration routes, and patient demographics. Application-wise, the dual pathways of diagnostic imaging and therapeutic treatment each demand distinct capabilities: diagnostic imaging emphasizes high-resolution PET and SPECT compatibility and workflow integration with diagnostic laboratories and imaging centers, while therapeutic treatment requires radioligand or small molecule therapy expertise along with capacity for radiohalogen or radiometal conjugation and post-therapy safety monitoring. Regarding molecule type, monoclonal antibodies, whether chimeric or humanized, bring established protein-engineering and regulatory precedents, while small molecules such as phosphoramidate or urea-based agents offer manufacturing simplicity and favorable pharmacokinetics that support broader administration strategies.

Cancer stage and treatment line stratification further tailor clinical positioning: agents positioned for localized disease must demonstrate diagnostic precision and minimal off-target toxicity, while therapies for advanced or metastatic disease must show durable therapeutic benefit and manageable safety profiles across first-line through third-line and beyond settings. End users span cancer treatment centers, diagnostic laboratories, hospital pharmacies, and research institutes, with cancer treatment centers differentiated into private and public settings that vary in procurement practices and reimbursement arrangements. Administration route-intravenous versus oral-impacts patient experience, facility requirements, and outpatient management, while patient age groups such as those under 65, 65 to 74, and 75 and above influence trial design, comorbidity considerations, and real-world uptake. Together, these axes of segmentation define distinct product profiles, go-to-market strategies, and evidence requirements for stakeholders across the value chain.

Regional clinical and commercial dynamics that drive differentiated adoption pathways for PSMA diagnostics and therapeutics across the Americas, EMEA, and Asia-Pacific

Regional dynamics create differentiated clinical, regulatory, and commercial environments that influence how PSMA inhibitor programs are developed and deployed. In the Americas, advanced imaging infrastructure, established reimbursement mechanisms for novel diagnostics in many jurisdictions, and concentrated centers of clinical excellence enable rapid trial enrollment and early adoption of theranostic approaches; however, payer variability across public and private systems requires tailored pricing and evidence-generation strategies. In Europe, Middle East & Africa, regulatory heterogeneity and variable access to specialized radiopharmacy capacity mean that centralized manufacturing models often coexist with nascent local production, and stakeholders must navigate a mosaic of reimbursement policies and referral pathways that affect adoption timelines.

In the Asia-Pacific region, rapid investment in oncology infrastructure, coupled with large patient populations and expanding clinical trial activity, presents significant opportunities for scale. Government initiatives to strengthen local manufacturing capability and to expedite regulatory pathways for innovative therapies are notable, and partnerships with regional contract manufacturers and academic centers can accelerate clinical development. Across all regions, logistical considerations for isotope supply and cold-chain integrity are critical, and regional strategies that combine local production, cross-border collaboration, and capacity-building initiatives will determine how quickly new PSMA-targeted diagnostics and therapeutics move from clinical validation to routine clinical practice.

Competitive and collaborative industry behaviors emphasizing integrated ligand innovation, radiochemistry scale-up, and strategic partnerships to secure clinical and supply chain advantages

Organizational strategies across the competitive landscape reveal a focus on integrated capabilities that bridge discovery, radiochemistry scale-up, clinical validation, and commercial logistics. Innovative biotech firms are concentrating on optimizing ligand design, improving target affinity, and advancing small molecule constructs that facilitate both imaging and therapeutic conjugation. Established pharmaceutical companies are leveraging their regulatory expertise, manufacturing scale, and payer relationships to accelerate late-stage development and to negotiate supply agreements with health systems and group purchasing organizations. Meanwhile, specialized radiopharmaceutical manufacturers and contract development and manufacturing organizations are expanding capabilities for isotope handling, automated synthesis, and aseptic fill-finish to meet the unique requirements of radioligand therapies.

Strategic partnerships, licensing deals, and co-development arrangements are common mechanisms for addressing capability gaps. Collaborations between diagnostic developers and therapy sponsors enable linked companion diagnostic strategies that strengthen clinical adoption, while alliances with regional manufacturing partners mitigate logistical constraints and support local reimbursement engagement. Intellectual property strategies emphasize both core ligand chemistries and proprietary conjugation processes, and companies are also investing in production redundancies and quality systems to ensure continuity of supply. These convergent strategies indicate that successful competitors will combine scientific differentiation with operational excellence and pragmatic commercial partnerships.

Actionable recommendations for executives to align scientific innovation, supply chain resilience, regulatory engagement, and payer-focused evidence generation for PSMA programs

Industry leaders must adopt proactive strategies that align scientific development with supply chain resilience, regulatory engagement, and payer-centric evidence generation. First, prioritize platform flexibility by investing in ligand chemistries and conjugation techniques that can be adapted for both imaging and therapeutic use; platform versatility reduces time-to-market for new indications and enables more efficient use of clinical trial assets. Second, mitigate supply-side risk by diversifying isotope sources and by developing regional manufacturing partnerships that reduce dependency on single geographies; nearshoring and collaborative manufacturing agreements can secure clinical supply in volatile trade environments.

Third, engage early and continuously with regulators and payers to define acceptable clinical endpoints and real-world evidence pathways that reflect therapeutic value. Early alignment shortens approval timelines and reduces downstream reimbursement uncertainty. Fourth, pursue integrated commercialization models that couple diagnostic adoption with therapeutic rollout, ensuring that companion diagnostic access does not become a bottleneck for therapy uptake. Finally, invest in real-world data systems and patient-support services that demonstrate safety, adherence, and health-economic value in diverse care settings and across patient age cohorts. These recommendations together create a balanced approach that addresses scientific differentiation, commercial viability, and operational robustness.

A reproducible and transparent research methodology combining primary expert interviews, technical literature review, and cross-validated scenario analysis to support strategic decision-making

This analysis synthesizes evidence from structured primary research, secondary literature, and rigorous cross-validation to ensure the reliability and relevance of conclusions. Primary research included interviews with clinical investigators, radiopharmacy directors, regulatory affairs leaders, and commercial decision-makers to capture real-world insights into trial design, production constraints, and payer negotiations. Secondary research incorporated peer-reviewed clinical studies, regulatory guidance documents, trial registries, and technical literature on radiochemistry and conjugation methods to ground findings in established science. These data sources were triangulated using a reproducible framework that reconciles clinical evidence, operational feasibility, and commercial impact.

Quantitative and qualitative inputs were integrated through iterative analytic steps that included validation workshops with subject matter experts and sensitivity checks on operational assumptions. Where appropriate, findings were contextualized by comparing cross-regional regulatory timelines and supply chain configurations to identify structural drivers of adoption. Quality assurance processes included source attribution, expert peer review, and scenario testing to verify that conclusions remain robust under plausible variations in supply, regulatory, and reimbursement conditions. The methodology emphasizes transparency and reproducibility so that stakeholders can trace the evidentiary basis for key conclusions and adapt the approach to organization-specific risk tolerances and strategic priorities.

Synthesis of strategic imperatives showing how clinical innovation, operational planning, and stakeholder alignment converge to advance PSMA-targeted care delivery

The PSMA inhibitor domain has matured into a complex ecosystem where scientific innovation, manufacturing capabilities, regulatory alignment, and payer expectations intersect to determine clinical impact and commercial success. Diagnostic imaging and therapeutic modalities are increasingly interdependent, creating opportunities for integrated product strategies that deliver precision patient selection and targeted treatment. At the same time, operational realities such as isotope sourcing, radiopharmacy capacity, and the structure of regional healthcare systems materially influence how and when new therapies reach patients. Strategic clarity-rooted in rigorous evidence generation, supply chain diversification, and early stakeholder alignment-will be decisive for organizations seeking leadership in this space.

In closing, the most resilient and successful entrants will be those that combine technical differentiation with pragmatic operational planning and a clear value narrative for payers and clinicians. By aligning clinical strategy, manufacturing investment, and commercial execution, organizations can translate the promise of PSMA-targeted approaches into sustained improvements in patient outcomes and durable commercial performance. The insights in this report are designed to accelerate that alignment and to inform practical next steps for development teams, commercial leaders, and policy stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate-Specific Membrane Antigen Inhibitor Market, by Molecule Type

  • 8.1. Monoclonal Antibody
    • 8.1.1. Chimeric
    • 8.1.2. Humanized
  • 8.2. Small Molecule
    • 8.2.1. Phosphoramidate
    • 8.2.2. Urea-Based

9. Prostate-Specific Membrane Antigen Inhibitor Market, by Cancer Stage

  • 9.1. Advanced
  • 9.2. Localized
  • 9.3. Metastatic

10. Prostate-Specific Membrane Antigen Inhibitor Market, by Treatment Line

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Prostate-Specific Membrane Antigen Inhibitor Market, by Administration Route

  • 11.1. Intravenous
  • 11.2. Oral

12. Prostate-Specific Membrane Antigen Inhibitor Market, by Patient Age Group

  • 12.1. 65 To 74
  • 12.2. 75 And Above
  • 12.3. Under 65

13. Prostate-Specific Membrane Antigen Inhibitor Market, by Application

  • 13.1. Diagnostic Imaging
    • 13.1.1. Pet Imaging
    • 13.1.2. Spect Imaging
  • 13.2. Therapeutic Treatment
    • 13.2.1. Radioligand Therapy
      • 13.2.1.1. Radiohalogen Conjugate
      • 13.2.1.2. Radiometal Conjugate
    • 13.2.2. Small Molecule Therapy

14. Prostate-Specific Membrane Antigen Inhibitor Market, by End User

  • 14.1. Cancer Treatment Centers
    • 14.1.1. Private
    • 14.1.2. Public
  • 14.2. Diagnostic Laboratories
  • 14.3. Hospital Pharmacies
  • 14.4. Research Institutes

15. Prostate-Specific Membrane Antigen Inhibitor Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Prostate-Specific Membrane Antigen Inhibitor Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Prostate-Specific Membrane Antigen Inhibitor Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Prostate-Specific Membrane Antigen Inhibitor Market

19. China Prostate-Specific Membrane Antigen Inhibitor Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Blue Earth Diagnostics Ltd
  • 20.6. Cardinal Health, Inc.
  • 20.7. Curium US LLC
  • 20.8. Eckert & Ziegler AG
  • 20.9. ITM Isotope Technologies Munich SE
  • 20.10. Lantheus Holdings, Inc.
  • 20.11. Novartis AG
  • 20.12. Pfizer Inc.
  • 20.13. RayzeBio, Inc.
  • 20.14. Siemens Healthineers AG
  • 20.15. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PHOSPHORAMIDATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PHOSPHORAMIDATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PHOSPHORAMIDATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UREA-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UREA-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UREA-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADVANCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADVANCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADVANCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY LOCALIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY LOCALIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY LOCALIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY METASTATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY METASTATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY METASTATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 65 TO 74, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 65 TO 74, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 75 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 75 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 75 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UNDER 65, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UNDER 65, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UNDER 65, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PET IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PET IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SPECT IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SPECT IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SPECT IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOHALOGEN CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOHALOGEN CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOHALOGEN CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOMETAL CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOMETAL CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOMETAL CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-20